RocheのLunsumio皮下注製剤、再発・難治性濾胞性リンパ腫に対しEUで条件付き承認 外来投与が約1分に短縮 | STELLANEWS.LIFE Rocheは、再発または難治性濾胞性リンパ腫に対するLunsumio（mosunetuzumab）皮下注製剤が欧州委員会より条件付き販売承認を取得したと発表。投与時間の短縮や有効性、安全性が第1／2相試験で確認され、外来投与の利便性向上に寄与。

Roche’s Lunsumio SC Granted Conditional EU Approval for Relapsed/Refractory Follicular Lymphoma

🔗 Full article: stellanews.life/technology_c...

#Roche #Lunsumio #Mosunetuzumab #FollicularLymphoma #Hematology #CancerTherapy #Subcutaneous #OncologyNews #Biopharma

Study S2308 compares 2 drugs for follicular lymphoma with low tumor burden

Follicular #lymphoma with low tumor burden is slow growing. #Clinicaltrial S2308 asks if using the drug #mosunetuzumab as early treatment can keep signs and symptoms of this cancer away for longer. SWOG.org/S2308. 1-800-4-CANCER. #lymsm @llsusa.bsky.social @lymphomadoc.bsky.social

Matching-Adjusted Indirect Comparison of Efficacy and Safety of #liso-cel and #Mosunetuzumab for the Treatment (Tx) of 3L+ R/R #FollicularLymphoma
... more and more excellent options for our more advanced patients.
ash.confex.com/ash/2023/web...